Company registration number 04184029 (England and Wales)
STORZ MEDICAL (UK) LIMITED
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
PAGES FOR FILING WITH REGISTRAR
STORZ MEDICAL (UK) LIMITED
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 8
STORZ MEDICAL (UK) LIMITED
BALANCE SHEET
AS AT
31 DECEMBER 2025
31 December 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Tangible assets
4
11,186
13,583
Current assets
Stocks
42,892
109,010
Debtors
5
246,704
645,660
Cash at bank and in hand
875,892
84,256
1,165,488
838,926
Creditors: amounts falling due within one year
6
(707,588)
(463,535)
Net current assets
457,900
375,391
Total assets less current liabilities
469,086
388,974
Provisions for liabilities
(2,620)
(3,204)
Net assets
466,466
385,770
Capital and reserves
Called up share capital
20,000
20,000
Profit and loss reserves
446,466
365,770
Total equity
466,466
385,770

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The director of the company has elected not to include a copy of the statement of income and retained earnings within the financial statements.true

The financial statements were approved and signed by the director and authorised for issue on 1 April 2026
M Merk
Director
Company registration number 04184029 (England and Wales)
STORZ MEDICAL (UK) LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
- 2 -
1
Accounting policies
Company information

Storz Medical (UK) Limited is a private company limited by shares incorporated in England and Wales. The registered office is 12 Cumberland Avenue, Park Royal, London, England, NW10 7QL.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

A true t the time of approving the financial statements, t he director has a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. The financial position of the company is stable, with access to signficant cash reserves and the ability to draw upon the support of the parent company if required. Thus t he director continues to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Turnover

The turnover of the company is derived from the sale of medical equipment and the provision of maintenance contracts to service medical equipment.

Turnover arising from the sale of medical equipment is recognised when the medical equipment is delivered and the significant risks and rewards of ownership are transferred to the customer.

Turnover arising from the installation of medical equipment is recognised when the medical equipment has been installed and is operational.

Turnover arising from maintenance contracts is recognised over the course of the contract when the company is entitled to recognise the revenue.

All turnover is recognised exclusive of Value Added Tax.

1.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost of assets less their residual values over their useful lives on the following bases:

Fixtures and fittings
20% straight line
Equipment
50% straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

STORZ MEDICAL (UK) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 3 -
1.5
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.6
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand and deposits held at call with banks.

1.7
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Impairment of financial assets

Financial assets, other than those held at fair value through profit and loss, are assessed for indicators of impairment at each reporting end date.

Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss.

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.

Derecognition of financial assets

Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the company transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

STORZ MEDICAL (UK) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 4 -
Basic financial liabilities

Basic financial liabilities, including creditors and loans from fellow group companies are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future paymen ts discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. A m ounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the company’s contractual obligations expire or are discharged or cancelled.

1.8
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.9
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the income statement, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

STORZ MEDICAL (UK) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 5 -
1.10
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.11
Retirement benefits

The company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the company pays fixed contributions into a separate entity. Once the contributions have been paid the company has no further payment obligations.

The contributions are recognised as an expense in the income statement when they fall due. Amounts not paid are shown within other creditors as a liability in the balance sheet. The assets of the plan are held separately from the company in independently administered funds.

1.12
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the lease s asset are consumed.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
4
4
STORZ MEDICAL (UK) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 6 -
4
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 January 2025
37,217
Additions
2,859
Disposals
(4,278)
At 31 December 2025
35,798
Depreciation and impairment
At 1 January 2025
23,634
Depreciation charged in the year
5,256
Eliminated in respect of disposals
(4,278)
At 31 December 2025
24,612
Carrying amount
At 31 December 2025
11,186
At 31 December 2024
13,583
5
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
168,295
626,852
Amounts owed by group undertakings
10,524
7,970
Other debtors
67,885
10,838
246,704
645,660
6
Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
8,771
14,298
Amounts owed to group undertakings
193,784
8,015
Corporation tax
28,407
10,527
Other taxation and social security
154,291
75,586
Other creditors
322,335
355,109
707,588
463,535
STORZ MEDICAL (UK) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 7 -
7
Audit report information

As the statement of income and retained earnings has been omitted from the filing copy of the financial statements, the following information in relation to the audit report on the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006.

The auditor's report is unqualified and includes the following:

Opinion

In our opinion the financial statements:

- give a true and fair view of the state of the company's affairs as at 31 December 2025 and of its profit for the year then ended;

- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and

- have been prepared in accordance with the requirements of the Companies Act 2006.

Senior Statutory Auditor:
Neil Kelly BA FCA
Statutory Auditor:
JS. Audit Limited
Date of audit report:
10 April 2026
STORZ MEDICAL (UK) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 8 -
8
Operating lease commitments
As lessee

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2025
2024
£
£
Total commitments
31,426
26,251
9
Events after the reporting date

On 5 February 2026, the director recommended and paid a final dividend of £400,000 in respect of the year ended 31 December 202 5.

10
Related party transactions

The entity has taken advantage of the exemption not to disclose related party transactions between wholly owned subsidiaries under FRS102 Section 33.1A.

11
Parent company

The immediate parent undertaking is Storz Medical AG which is the parent of the smallest group for which consolidated financial statements are prepared, of which the company is a member. The registered office address of Storz Medical AG is Lohstampfestrasse 8, Ch-8274, Tägerwilen, Switzerland.

2025-12-31 2025-01-01 false false false 10 April 2026 CCH Software CCH Accounts Production 2025.300 No description of principal activity M Merk P Schmid 04184029 2025-01-01 2025-12-31 04184029 2025-12-31 04184029 2024-12-31 04184029 core:OtherPropertyPlantEquipment 2025-12-31 04184029 core:OtherPropertyPlantEquipment 2024-12-31 04184029 core:CurrentFinancialInstruments core:WithinOneYear 2025-12-31 04184029 core:CurrentFinancialInstruments core:WithinOneYear 2024-12-31 04184029 core:CurrentFinancialInstruments 2025-12-31 04184029 core:CurrentFinancialInstruments 2024-12-31 04184029 core:ShareCapital 2025-12-31 04184029 core:ShareCapital 2024-12-31 04184029 core:RetainedEarningsAccumulatedLosses 2025-12-31 04184029 core:RetainedEarningsAccumulatedLosses 2024-12-31 04184029 bus:Director1 2025-01-01 2025-12-31 04184029 core:FurnitureFittings 2025-01-01 2025-12-31 04184029 core:ComputerEquipment 2025-01-01 2025-12-31 04184029 2024-01-01 2024-12-31 04184029 core:OtherPropertyPlantEquipment 2024-12-31 04184029 core:OtherPropertyPlantEquipment 2025-01-01 2025-12-31 04184029 bus:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 04184029 bus:SmallCompaniesRegimeForAccounts 2025-01-01 2025-12-31 04184029 bus:FRS102 2025-01-01 2025-12-31 04184029 bus:Audited 2025-01-01 2025-12-31 04184029 bus:CompanySecretary1 2025-01-01 2025-12-31 04184029 bus:FullAccounts 2025-01-01 2025-12-31 xbrli:pure xbrli:shares iso4217:GBP